Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) specializes in diabetes management solutions, focusing on insulin pumps. The stock showed a bearish trend today amid recent developments and an upcoming earnings release.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.1% on Feb 12, 2026 20:26

• TNDM stock faced a bearish movement possibly linked to ongoing investigations related to potential securities claims by The Rosen Law Firm and a previous stock decline after a voluntary medical device correction announcement.
• The expected loss per share in the upcoming earnings report may have further dampened investor sentiment towards the stock.
• Investor concerns about the reliability and safety of Tandem's insulin pumps, as highlighted in ongoing investigations, likely contributed to selling pressure and uncertainty.
• The convergence of these factors is believed to have influenced the bearish market activity in TNDM stock today.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care (TNDM) to Release Earnings on Thursday

Tandem Diabetes Care (TNDM) is scheduled to release its Q4 2025 earnings after the market closes on Thursday, February 19th. Analysts anticipate a loss of ($0.06) per share and revenue of $277.144 million. The stock opened at $19.66 with a market cap of $1.33 billion and currently holds a consensus "Hold" rating from analysts with a target price of $24.35.

https://www.marketbeat.com/instant-alerts/tandem-diabetes-care-tndm-to-release-earnings-on-thursday-2026-02-12/

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), ...

The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations of materially misleading business information. This investigation stems from the company's August 7, 2023, announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential error causing insulin delivery discontinuation, which led to a nearly 20% stock drop. Shareholders who suffered losses are encouraged to contact the firm for potential class action recovery.

https://www.bdtonline.com/news/nation_world/tndm-investor-news-if-you-have-suffered-losses-in-tandem-diabetes-care-inc-nasdaq-tndm/article_0a8ecae9-0ffa-500e-ae53-9de0d1c4a360.html

TNDM Investor News: If You Have Suffered Losses in Tandem

The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following a significant stock drop on August 7, 2025, after the company announced a voluntary medical device correction for its t:slim X2 insulin pumps. The firm encourages investors who purchased Tandem Diabetes securities and suffered losses to contact them to join a prospective class action lawsuit. This investigation aims to recover investor losses due to allegedly misleading business information.

https://www.globenewswire.com/news-release/2026/02/08/3234208/673/en/TNDM-Investor-News-If-You-Have-Suffered-Losses-in-Tandem-Diabetes-Care-Inc-NASDAQ-TNDM-You-Are-Encouraged-to-Contact-The-Rosen-Law-Firm-About-Your-Rights.html

Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

The Rosen Law Firm is investigating potential securities class action claims against Tandem Diabetes Care, Inc. (TNDM) following a significant stock drop. The investigation stems from a voluntary medical device correction announcement for select t:slim X2 insulin pumps due to a speaker-related issue that could disrupt insulin delivery, causing the stock to fall 19.9% on August 7, 2025. Investors who purchased Tandem Diabetes securities are encouraged to contact the firm to potentially recover losses.

https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-tandem-diabetes-care-inc-investors-to-inquire-about-securities-class-action-investigation--tndm-302681787.html

Trending Today

POL (Polygon) ($POL) Crypto Forecast: Up 8.8% Today

Silver ($XAG) Commodity Forecast: Down 8.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 5.1% Today

Iron Mountain Incorporated (Delaware)Common Stock REIT ($IRM) Stock Forecast: Up 5.2% Today

Marathon Petroleum Corporation ($MPC) Stock Forecast: Down 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Down 5.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 5.0% Today

Gartner Inc. ($IT) Stock Forecast: Down 5.1% Today

CBRE Group Inc Class A ($CBRE) Stock Forecast: Down 8.3% Today

Lincoln National Corporation ($LNC) Stock Forecast: Up 5.4% Today

Tandem Diabetes Care, Inc. Price History

21.00.2026 - TNDM Stock was up 5.1%

• TNDM's stock price has increased by 36.3% in the last three months despite previous declines, which likely contributed to today's positive movement.
• An inquiry into potential securities claims against TNDM and concerns about misleading business information may have led to an initial stock price drop. However, today's market response suggests growing confidence in the company's future.
• Issues with certain t:slim X2 insulin pumps resulted in a significant stock decrease, causing investor unease. The subsequent recovery indicates a reevaluation of the pumps' impact on TNDM's performance.
• Analysts considering TNDM undervalued and providing fair value estimates based on projected growth and product advancements possibly influenced today's bullish activity, reflecting investor optimism about the company's future prospects.

30.00.2026 - TNDM Stock was up 6.0%

• The positive movement in TNDM is attributed to an improved growth outlook and strong Q4 results, as indicated in an investor letter by Meridian Growth Fund.
• Despite facing a legal investigation related to a voluntary correction for its insulin pumps, TNDM is seen as undervalued, sparking investor interest in the stock.
• An article raising concerns about weak sales volumes and declining ROIC might have initially impacted the stock negatively, but overall optimism about growth prospects and product advancements likely drove the bullish movement.
• Investors are focusing on TNDM's growth potential in the diabetes care market and product innovations, disregarding short-term challenges, which has driven the stock price higher.

13.00.2026 - TNDM Stock was down 5.1%

• Despite reporting a loss in Q3, Tandem Diabetes Care surpassed revenue expectations, showcasing resilience amid market challenges. The wider loss possibly influenced the downturn in the stock price.
• Speculation surrounding the forthcoming Q4 earnings report, which is anticipated to show a revenue decrease and increased loss, might have impacted the stock negatively.
• Investor concern persists regarding Tandem Diabetes Care's struggle with profitability, awaiting the company's future guidance and growth strategies following the Q4 financial results disclosure.
• The market's response to the news of the upcoming financial results release on February 19, 2026, potentially prompted profit-taking and selling activity, driving the bearish trend in TNDM stock.

22.11.2025 - TNDM Stock was up 5.1%

• The bullish movement in TNDM stock could be attributed to the recent launch of the t:slim mobile application in Canada, expanding the company's reach and enhancing its integrated diabetes management solutions.
• Despite challenges with a voluntary medical device correction for its t:slim X2 insulin pumps due to a speaker-related issue, the stock managed to rebound, possibly due to a recent upgrade of Tandem Diabetes Care, reflecting an improved outlook for the company.
• Ongoing investigations by a law firm regarding potential securities claims and class action lawsuits might have initially caused a drop in the stock price, but the market's positive response to the company's product expansion and analyst upgrade helped drive the bullish movement.

09.00.2026 - TNDM Stock was down 9.7%

• Today's downward movement in TNDM stock could be tied to market expectations for the upcoming Q4 2025 earnings. Analysts foresee a decline in revenue and a wider loss compared to the previous year. Key metrics such as gross margin, pump shipments, and international sales are closely watched, prompting investors to review their positions. Concerns about the company's market position and growth strategies might have shifted market sentiment, leading to a stock sell-off.

03.01.2026 - TNDM Stock was down 7.0%

• TNDM faced a downward trend following the announcement of a voluntary medical device correction for its t:slim X2 insulin pumps.
• The correction addressed a possible speaker-related issue that could disrupt insulin delivery, sparking concerns about the product's reliability.
• A probe by the Rosen Law Firm into potential securities claims exacerbated the negative sentiment surrounding TNDM and led to a significant drop in the stock price.
• Investors reacted strongly to these developments, reflecting apprehensions about the potential impact on Tandem Diabetes Care's financial performance and reputation.

12.01.2026 - TNDM Stock was down 5.1%

• TNDM stock faced a bearish movement possibly linked to ongoing investigations related to potential securities claims by The Rosen Law Firm and a previous stock decline after a voluntary medical device correction announcement.
• The expected loss per share in the upcoming earnings report may have further dampened investor sentiment towards the stock.
• Investor concerns about the reliability and safety of Tandem's insulin pumps, as highlighted in ongoing investigations, likely contributed to selling pressure and uncertainty.
• The convergence of these factors is believed to have influenced the bearish market activity in TNDM stock today.

28.00.2026 - TNDM Stock was down 5.1%

• The improved growth outlook and better-than-expected results in Q4 boosted TNDM initially, but concerns over weak sales volumes, declining ROIC, and restricted access to capital led to a bearish movement.
• The device correction for its insulin pumps and the securities probe raised doubts about the company's risk controls and disclosure practices, impacting investor confidence.
• The investigation into potentially misleading business information following the medical device correction announcement further added to the negative sentiment surrounding TNDM.
• Overall, the combination of regulatory challenges, financial concerns, and legal investigations likely contributed to the bearish movement in TNDM's stock today.

16.11.2025 - TNDM Stock was up 6.4%

• The company was upgraded to "Outperform" from "Neutral" by Baird, accompanied by an increased price target. This adjustment signals a favorable outlook on the company's financial future, potentially contributing to the upward movement.
• A previous investigation into a securities class action following a stock decline due to a voluntary medical device correction may have led to initial uncertainty and a decrease in the stock price. However, the subsequent positive outlook and upgrade likely played a role in driving the upward movement.
• While concerns existed regarding pump demand and negative EBITDA, the recent price surge and a possible undervaluation, as indicated by Simply Wall St's DCF model, could have attracted investors, thereby leading to the uptrend.
• In summary, a combination of optimistic analyst assessments, potential undervaluation, and anticipated future growth opportunities probably fueled today's upward movement in Tandem Diabetes Care's stock.

16.00.2026 - TNDM Stock was up 5.3%

• TNDM exceeded revenue expectations in Q3 despite facing a loss, demonstrating resilience amid market challenges.
• Analysts' consensus "Hold" rating on TNDM reflects a cautious outlook on the stock.
• Noteworthy institutional investors such as Assenagon Asset Management S.A. acquiring a considerable stake in TNDM may have fueled the bullish trend, indicating confidence in the company's future.
• AI-generated trading strategies have hinted at potential downside risks, causing some investors to consider this alongside TNDM's positive revenue performance.

05.00.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care (TNDM) saw a significant increase in its stock value due to various positive factors today:
• The company is part of a group of biotech companies leading advancements in diabetes treatments, moving beyond traditional insulin shots towards functional cures and regenerative medicine, which has captured investor interest and confidence in TNDM's future.
• The anticipated growth of the disposable insulin pumps market, where Tandem Diabetes Care plays a pivotal role, suggests a promising future for the company, with the rising adoption of tubeless patch pumps fueling market expansion.
• Recent updates made by Tandem Diabetes Care to its bylaws to strengthen governance rules illustrate a dedication to transparency and accountability, reassuring investors and potentially attracting new interest in the company.
• Significant purchases of Tandem Diabetes Care stock by key executives indicate a belief in the company's direction and future expansion, offering a positive perspective for investors and contributing to the upward movement in the stock price.

10.01.2026 - TNDM Stock was up 5.5%

• The bullish movement in TNDM stock today could be attributed to renewed investor interest following a recent decline and assessment of the company's valuation.
• Despite facing challenges such as the recent voluntary medical device correction for select insulin pumps, investors seem optimistic about Tandem Diabetes Care's future revenue growth and margin expansion potential.
• Analysis suggesting a near-term neutral sentiment might have also contributed to the stock's bullish movement, indicating a potential pause in the previous weakness and presenting favorable risk-reward setups for traders.